Mirabegron 50mg

Description

Mirabegron is an orally active, selective beta-3 ($\beta_3$) adrenergic receptor agonist. It is primarily prescribed for the treatment of Overactive Bladder (OAB) syndrome. Unlike traditional anticholinergic medications used for bladder control (such as oxybutynin or tolterodine), mirabegron does not target muscarinic receptors, which helps minimize common anticholinergic side effects like severe dry mouth, constipation, and cognitive impairment.

Mechanism of Action

1. $\beta_3$-Adrenoceptor Activation: Mirabegron binds selectively to $\beta_3$-adrenergic receptors located on the detrusor muscle of the bladder.

2. Smooth Muscle Relaxation: Activation of these receptors stimulates adenylate cyclase and increases intracellular cyclic adenosine monophosphate (cAMP), leading to detrusor muscle relaxation during the urine storage phase.

3. Increased Bladder Capacity: By facilitating relaxation without affecting the voiding phase, mirabegron increases volumetric bladder capacity and extends the intervals between urination without impairing bladder emptying.

Off-Label Research Context (Thermogenesis)

In physiological and clinical research, $\beta_3$-adrenergic agonists have been studied for their potential role in activating brown adipose tissue (BAT) and stimulating thermogenesis. While high-dose stimulation of $\beta_3$ receptors can influence metabolic rate in laboratory settings, Mirabegron is not approved by regulatory agencies (such as the FDA, EMA, or MHRA) as a weight loss agent, fat burner, or metabolic supplement.

Clinical Safety & Contraindications

• Cardiovascular Effects: Mirabegron can increase blood pressure and heart rate. It is contraindicated in patients with severe uncontrolled hypertension (e.g., systolic $\ge 180$ mmHg or diastolic $\ge 110$ mmHg). Regular blood pressure monitoring is recommended during treatment.

• Urinary Retention: Caution is advised when administering to patients with clinically significant bladder outlet obstruction (BOO) or those taking antimuscarinic medications for OAB.

• Drug Interactions: Mirabegron is a moderate inhibitor of CYP2D6. It increases the plasma concentrations of drugs metabolized by CYP2D6 (such as metoprolol, desipramine, and thioridazine).

• Common Side Effects: The most frequently reported adverse reactions include hypertension, nasopharyngitis, urinary tract infections (UTIs), and headache.